Arcus Biosciences Past Earnings Performance
Past criteria checks 0/6
Arcus Biosciences's earnings have been declining at an average annual rate of -23.6%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 39.1% per year.
Key information
-23.6%
Earnings growth rate
-11.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 39.1% |
| Return on equity | -66.5% |
| Net Margin | -262.4% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth
Mar 20
What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You
Feb 23Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment
Feb 22Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Dec 18Arcus Biosciences: Showing There Might Be Something To TIGIT After All
Dec 15Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?
Nov 30Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey
Nov 20Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Aug 29Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation
Aug 08Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates
Jun 15Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk
May 05Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17
Nov 02Analysts Just Slashed Their Arcus Biosciences, Inc. (NYSE:RCUS) EPS Numbers
May 12Arcus Biosciences: Not Much Data Yet, But Gilead Deal Is A Huge Value Add
Jan 07Forecast: Analysts Think Arcus Biosciences, Inc.'s (NYSE:RCUS) Business Prospects Have Improved Drastically
Nov 25Analysts Just Shaved Their Arcus Biosciences, Inc. (NYSE:RCUS) Forecasts Dramatically
Aug 08Need To Know: Analysts Are Much More Bullish On Arcus Biosciences, Inc. (NYSE:RCUS) Revenues
Jun 26Revenue & Expenses BreakdownBeta
How Arcus Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 117 | -307 | 117 | 305 |
| 30 Sep 23 | 120 | -293 | 116 | 0 |
| 30 Jun 23 | 121 | -287 | 112 | 0 |
| 31 Mar 23 | 119 | -279 | 110 | 0 |
| 31 Dec 22 | 112 | -267 | 104 | 255 |
| 30 Sep 22 | 433 | 80 | 99 | 0 |
| 30 Jun 22 | 409 | 67 | 89 | 0 |
| 31 Mar 22 | 392 | 58 | 80 | 0 |
| 31 Dec 21 | 383 | 53 | 72 | 228 |
| 30 Sep 21 | 38 | -278 | 62 | 0 |
| 30 Jun 21 | 93 | -199 | 57 | 0 |
| 31 Mar 21 | 85 | -168 | 51 | 0 |
| 31 Dec 20 | 78 | -123 | 43 | 0 |
| 30 Sep 20 | 78 | -88 | 36 | 0 |
| 30 Jun 20 | 15 | -112 | 33 | 0 |
| 31 Mar 20 | 15 | -95 | 27 | 0 |
| 31 Dec 19 | 15 | -85 | 25 | 0 |
| 30 Sep 19 | 7 | -80 | 22 | 0 |
| 30 Jun 19 | 9 | -69 | 18 | 0 |
| 31 Mar 19 | 9 | -54 | 16 | 0 |
| 31 Dec 18 | 8 | -50 | 14 | 0 |
| 30 Sep 18 | 8 | -51 | 12 | 0 |
| 30 Jun 18 | 4 | -63 | 11 | 0 |
| 31 Mar 18 | 3 | -59 | 9 | 0 |
| 31 Dec 17 | 1 | -53 | 8 | 0 |
Quality Earnings: RCUS is currently unprofitable.
Growing Profit Margin: RCUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RCUS is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.
Accelerating Growth: Unable to compare RCUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RCUS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: RCUS has a negative Return on Equity (-66.45%), as it is currently unprofitable.